Browse the evidence

THDBH120 is a novel long-acting dual GIPR/GLP-1R agonist that has superior weight loss and metabolic improvement effects in rodents and mammals.

THDBH120 may be a promising treatment option for obesity and metabolic disorders.

Perturbation of gut-brain-pancreas communication contributes to metabolic disorders such as obesity and type 2 diabetes.

Recognizing these perturbations can guide therapeutic approaches for metabolic disorders.

The presence of metabolic abnormalities doubles event rates associated with obesity, with risk increasing with the number of metabolic abnormalities present.

Practitioners should consider the presence of metabolic abnormalities when assessing the risks of obesity in patients.

Metabolic parameters such as glycaemic, blood pressure, and lipid levels return to baseline within approximately 12 months after discontinuation.

Healthcare providers should monitor metabolic parameters closely after discontinuation of GLP-1RA therapy.

At 2.5 years, White individuals experienced significantly greater body weight loss than Black individuals: −7.1% versus −4.9%.

Practitioners should be aware of racial differences in weight loss outcomes when prescribing GLP-1RA therapy.

White individuals had significantly larger reductions in estimated glomerular filtration rate, systolic blood pressure, and HbA1c compared to Black individuals.

Healthcare providers should consider these differences in clinical outcomes when treating patients with GLP-1RA.

Emerging single-anastomosis variants demonstrate promising efficacy and improved gastrointestinal profiles.

Clinicians should consider these emerging techniques for patients seeking bariatric surgery.

There was no significant effect of either whey or soy protein supplementation on lean body mass (LBM).

Practitioners should note that protein supplementation may not significantly increase lean body mass.

A high protein diet (PRO) had a limited benefit on metabolic flexibility compared to a control diet (CON).

While a high protein diet is beneficial, its impact on metabolic flexibility may not be significant for older adults.

Protein supplementation during aerobic training did not significantly enhance cardiorespiratory fitness compared with an isocaloric placebo.

Practitioners should consider that protein supplementation may not provide additional benefits for improving cardiorespiratory fitness in stroke patients undergoing aerobic training.

There was no significant relationship between body fat mass changes and daily protein intake.

Practitioners should note that increasing protein intake may not affect body fat loss in older women.

Insulin resistance in aging is a multisystem phenomenon reflecting declining metabolic adaptability rather than a simple glucose disorder.

Practitioners should consider insulin resistance as a complex, systemic issue in older patients, not just a glucose management problem.

Predisposing risk factors for antipsychotic-induced weight gain (AIWG) include lack of prior AP exposure, sex, and age.

Clinicians should consider these risk factors when prescribing antipsychotics.

A comprehensive redefinition of obesity in Asian Indians is needed beyond BMI criteria.

Practitioners should consider factors beyond BMI when diagnosing obesity in Asian Indians.

The refined framework aims to enhance precision in identifying obesity and its health risks.

Practitioners can use this framework to better assess obesity-related health risks.

Short term dietary trials are highly susceptible to bias due to physiological adaptation to major changes in nutrients.

Practitioners should be aware that results from short-term dietary trials may be influenced by the time it takes for physiological changes to occur.

GIPR agonism enhances the insulin-sensitizing effect of the thiazolidinedione rosiglitazone.

Incorporating GIPR agonists could enhance the effectiveness of insulin-sensitizing medications.

Anaerobic exercise decreases systemic pH and increases metabolic acidosis in athletes.

Athletes should be aware that anaerobic exercise can lead to increased metabolic acidosis.

Psychotropic medications, especially antipsychotics, cause weight gain in individuals with severe mental illness (SMI).

Practitioners should be aware of the weight gain side effects of antipsychotic medications in SMI patients.

Metformin and topiramate are commonly prescribed for weight gain in individuals with SMI, but their weight loss potential is modest.

Practitioners should consider the limited effectiveness of metformin and topiramate for weight management in SMI patients.

Current research has focused more on muscle mass than on skeletal muscle lipid metabolism.

Researchers should shift focus to skeletal muscle lipid metabolism in future studies.

Nearly half of all patients listed for kidney transplant have obesity, which is associated with increased rates of perioperative complications and graft loss.

Healthcare providers should be aware of the high prevalence of obesity in kidney transplant candidates and its implications for surgery.

Protein ingestion during hemodialysis does not attenuate hemodialysis efficacy.

Protein intake can be safely incorporated into hemodialysis routines.

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is projected to increase from 33.7% (86.3 million people) in 2020 to 41.4% (121.9 million people) by 2050.

Health systems should prepare for a significant increase in MASLD cases.